Provigil and PPIs (Omeprazole, Pantoprazole): Interaction Explained

What Is the Core Interaction Between Modafinil and PPIs?

The interaction between modafinil and PPIs is bidirectional and enzyme-mediated. Modafinil induces CYP2C19, the hepatic enzyme responsible for metabolizing omeprazole, esomeprazole, lansoprazole, and to a lesser degree pantoprazole. At the same time, omeprazole inhibits CYP2C19, slowing modafinil's own partial metabolism through that pathway. The net clinical result depends on dose, genetics, and which direction of the interaction dominates in a given patient.

How CYP2C19 Connects These Two Drugs

CYP2C19 is a cytochrome P450 isoform expressed primarily in the liver. It handles a disproportionate share of both drug classes involved here. Omeprazole is metabolized almost entirely by CYP2C19 and CYP3A4, and it also inhibits CYP2C19 in a dose-dependent fashion. Pantoprazole shares the same metabolic pathway but is a weaker CYP2C19 inhibitor, making it the preferred PPI in polypharmacy situations where CYP2C19 load is already high [1].

Modafinil's relationship with CYP2C19 runs in the opposite direction. The FDA-approved label for modafinil states explicitly that the drug is "a reversible inhibitor of CYP2C19 in vitro" at certain concentrations, and clinical pharmacokinetic studies demonstrate that modafinil induces CYP2C19-dependent metabolism at therapeutic doses [2]. This induction can reduce the AUC (area under the concentration-time curve) of co-administered CYP2C19 substrates by a clinically meaningful margin.

Direction 1: Omeprazole Raises Modafinil Exposure

Omeprazole's CYP2C19 inhibition can slow the hepatic clearance of modafinil's minor metabolic pathway through CYP2C19, raising modafinil plasma concentrations. A pharmacokinetic study published in Clinical Pharmacology and Therapeutics found that CYP2C19 inhibition by omeprazole increased AUC of CYP2C19 substrates by 40 to 100% in extensive metabolizers [3]. Modafinil patients on omeprazole 20 to 40 mg daily may therefore experience amplified wakefulness-promoting effects, insomnia, or cardiovascular stimulation at standard 200 mg doses.

Direction 2: Modafinil Reduces PPI Plasma Levels

Modafinil's induction of CYP2C19 accelerates the breakdown of omeprazole, reducing its plasma AUC and potentially lowering intragastric pH control. Adequate acid suppression typically requires an omeprazole AUC above a defined threshold to maintain gastric pH above 4 for a sufficient proportion of the day. When modafinil reduces that AUC, patients may experience breakthrough heartburn, worsening gastroesophageal reflux disease (GERD), or reduced Helicobacter pylori eradication rates if omeprazole forms part of a triple-therapy regimen [4].

How Significant Is This Interaction Clinically?

Most interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the modafinil-omeprazole combination as a moderate interaction. That classification reflects real pharmacokinetic changes that do not typically require emergency intervention, but do require clinical awareness and periodic reassessment.

Interaction Severity Breakdown by PPI

Different PPIs carry different interaction magnitudes with modafinil because their CYP2C19 inhibitory potencies differ substantially.

Omeprazole (Prilosec): The strongest CYP2C19 inhibitor among commonly used PPIs. A single 40 mg dose of omeprazole raises the AUC of CYP2C19 substrates by approximately 30 to 40% in CYP2C19 extensive metabolizers [3]. In poor metabolizers, the AUC increase can exceed 100%.

Esomeprazole (Nexium): The S-enantiomer of omeprazole. It shares a similar CYP2C19 inhibitory profile and should be regarded as roughly equivalent to omeprazole for interaction-risk purposes.

Lansoprazole (Prevacid): A moderate CYP2C19 inhibitor, with less potent inhibition than omeprazole. The interaction with modafinil exists but is expected to be smaller in magnitude.

Pantoprazole (Protonix): The weakest CYP2C19 inhibitor in the PPI class. A 2007 pharmacokinetic study in Alimentary Pharmacology and Therapeutics demonstrated that pantoprazole produces minimal CYP2C19 inhibition at standard 40 mg doses, making it the most interaction-neutral PPI choice when a patient requires concurrent acid suppression with a CYP2C19-sensitive drug [5].

Rabeprazole (Aciphex): Metabolized primarily through non-enzymatic reduction rather than CYP2C19, so its CYP2C19 inhibitory effect is also low, comparable to pantoprazole.

Population-Level Variation: CYP2C19 Genetics Matter

CYP2C19 genotype profoundly changes the magnitude of this interaction. Approximately 2 to 5% of White and Black populations and 12 to 23% of Asian populations are CYP2C19 poor metabolizers, meaning they carry two loss-of-function alleles (*2/*2 or *2/*3) and metabolize CYP2C19 substrates far more slowly [6]. In poor metabolizers, baseline omeprazole AUC is already 10-fold higher than in extensive metabolizers. Adding modafinil's partial CYP2C19 inhibition to that background further complicates clearance predictions.

Conversely, CYP2C19 ultra-rapid metabolizers (approximately 5% of White populations, higher in some African populations) may metabolize both drugs so quickly that neither accumulates to concerning levels.

The American College of Gastroenterology 2022 clinical guidelines on GERD management note that "CYP2C19 polymorphisms substantially affect PPI pharmacokinetics and clinical response" and recommend considering PPI dose adjustment or genotype-guided selection when drug interactions are expected [7].

Absorption-Level Effects: Does Gastric pH Change Modafinil Absorption?

This is a distinct, secondary mechanism worth addressing. PPIs raise intragastric pH from approximately 1 to 2 up to 4 to 6 during the dosing interval. For drugs with pH-dependent solubility, that shift meaningfully changes absorption. Modafinil, however, is a weakly acidic compound with a pKa of approximately 10.4 and good solubility across the physiologically relevant pH range. Its bioavailability is not expected to change meaningfully with gastric pH elevation [2].

This means the absorption component of the interaction is not clinically significant for modafinil specifically, which separates it from drugs like itraconazole or atazanavir where PPI-induced pH elevation substantially reduces absorption.

FDA Label Guidance on Modafinil Drug Interactions

The FDA-approved prescribing information for modafinil (Provigil) contains a dedicated drug-interaction section. Two passages are particularly relevant:

The label states: "Modafinil is a weak to moderate inducer of CYP3A4/5 and an inhibitor of CYP2C19 and may alter the plasma concentrations of drugs that are substrates for CYP3A4/5 or CYP2C19." [2]

The label also specifies: "Dose adjustments may be necessary for patients being treated with drugs that are substrates for CYP2C19 (e.g., omeprazole, phenytoin, diazepam, propranolol, tricyclic antidepressants)." [2]

This language directly names omeprazole as a substrate requiring attention. Pantoprazole is not named individually, but it shares the same metabolic pathway and the same guidance applies by pharmacological extension.

Monitoring Parameters and Clinical Decision-Making

When a patient is on both modafinil and a PPI, the following structured monitoring approach can reduce adverse outcomes.

Step 1: Assess the PPI Indication and Dose

Determine whether the PPI is being used for an episodic indication (e.g., short-course GERD) or a chronic one (e.g., Barrett's esophagus, long-term NSAID prophylaxis, H. Pylori eradication). Chronic high-dose omeprazole (40 mg twice daily) carries greater interaction potential than short-course 20 mg once daily use.

If the clinical indication allows, switching from omeprazole to pantoprazole 40 mg daily reduces the CYP2C19 inhibitory burden while maintaining adequate acid suppression for most GERD patients.

Step 2: Evaluate the Modafinil Dose

Standard modafinil dosing for narcolepsy and shift-work sleep disorder is 200 mg once daily, taken in the morning. The FDA label permits up to 400 mg daily, though evidence for additional benefit above 200 mg is limited [2]. Patients on 400 mg daily carry greater CYP2C19 induction potential and a correspondingly larger risk of reducing PPI efficacy.

Step 3: Check CYP2C19 Phenotype If Available

Pharmacogenomic testing for CYP2C19 (e.g., through a panel that includes *2, *3, and *17 alleles) is increasingly accessible through commercial labs and some telehealth platforms. Poor metabolizers starting modafinil while on omeprazole may need their omeprazole dose reduced, or a switch to pantoprazole or rabeprazole, to avoid accumulation-driven adverse effects.

Step 4: Monitor Symptom Endpoints

For the PPI direction of the interaction, the monitoring target is symptom control. Patients should be asked within 2 to 4 weeks of starting modafinil whether they have noticed a return of heartburn, regurgitation, or dyspepsia that was previously controlled. If breakthrough acid symptoms appear, options include:

• Increasing the PPI dose (e.g., from pantoprazole 40 mg daily to 40 mg twice daily)
• Switching from omeprazole to pantoprazole if not already on it
• Adding a short course of H2 receptor antagonist (e.g., famotidine 20 mg at bedtime) for nocturnal breakthrough symptoms

For the modafinil direction, monitor for signs of excessive drug effect: prolonged insomnia, headache, tachycardia, or anxiety. These may indicate raised modafinil plasma levels secondary to CYP2C19 inhibition by omeprazole.

Special Populations and Scenarios

H. Pylori Eradication Regimens

Omeprazole is a standard component of triple therapy for H. Pylori eradication (omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1 g, all twice daily for 14 days). Eradication success rates are pH-dependent, requiring sustained gastric pH above 5 throughout treatment. A 2020 meta-analysis in Alimentary Pharmacology and Therapeutics (N=47 trials) confirmed that CYP2C19 rapid metabolizers achieve lower eradication rates with standard-dose PPI-based triple therapy than poor metabolizers, with odds ratios in the range of 0.6 to 0.7 [8].

Adding modafinil during an H. Pylori eradication course could further reduce omeprazole AUC in extensive metabolizers, potentially pushing eradication rates below the acceptable threshold of 90% per American College of Gastroenterology standards. If possible, either pause modafinil during the 14-day eradication course or switch omeprazole to rabeprazole, which is less susceptible to CYP2C19 variation.

Patients With Cardiovascular Disease

Modafinil carries a label warning for patients with serious cardiac conditions, including left ventricular hypertrophy and mitral valve prolapse. If omeprazole raises modafinil plasma concentrations in these patients, the risk of tachycardia or palpitations may increase. A baseline ECG is reasonable for cardiac patients before initiating modafinil, and dose titration should start at 100 mg daily rather than 200 mg.

Elderly Patients

Hepatic CYP2C19 activity declines modestly with age, and older adults commonly take both PPIs (for GERD, peptic ulcer disease prophylaxis) and modafinil or armodafinil (for shift-work or off-label fatigue in conditions like multiple sclerosis or cancer-related fatigue). The combination of age-related CYP2C19 decline plus omeprazole-mediated CYP2C19 inhibition could meaningfully raise modafinil exposure. Starting at 100 mg daily and titrating based on response is prudent in patients over 65.

Practical Patient Counseling Points

Patients starting modafinil while already on a PPI, or vice versa, deserve clear, specific guidance:

1. Tell your prescriber about all acid medications. OTC omeprazole (Prilosec OTC, 20 mg) is widely used without physician involvement and is not always captured in medication reconciliation. Patients should proactively disclose it.

2. Watch for returning reflux symptoms. If heartburn or regurgitation returns within a few weeks of starting modafinil, contact the prescribing clinician before stopping or doubling the PPI dose independently.

3. Watch for amplified stimulant effects. New insomnia, racing heart, or agitation after starting omeprazole while already on modafinil may signal rising drug levels. Report these symptoms promptly.

4. Timing adjustments do not resolve this interaction. Because the mechanism is hepatic enzyme inhibition and induction rather than absorption competition, separating the doses by an hour or two does not meaningfully reduce the pharmacokinetic effect.

5. Pantoprazole is often a reasonable substitute. If acid suppression is needed and the interaction is a concern, pantoprazole 40 mg daily provides similar clinical acid control with a lower CYP2C19 inhibitory burden.

Comparing Interaction Risk Across the PPI Class

The table below summarizes relative CYP2C19 inhibitory potency and expected interaction magnitude with modafinil for each major PPI.

| PPI | CYP2C19 Inhibition Strength | Expected Modafinil AUC Increase | Preferred in Polypharmacy? | |---|---|---|---| | Omeprazole 20-40 mg | Strong | Moderate (approx. 30-60%) | No | | Esomeprazole 20-40 mg | Strong | Moderate (approx. 30-60%) | No | | Lansoprazole 15-30 mg | Moderate | Small to moderate | Neutral | | Pantoprazole 40 mg | Weak | Minimal | Yes | | Rabeprazole 20 mg | Weak | Minimal | Yes |

Data extrapolated from CYP2C19 inhibitory Ki values and clinical pharmacokinetic studies cited in [3] and [5].

What the Evidence Base Looks Like

Direct head-to-head pharmacokinetic trials specifically enrolling patients on both modafinil and a PPI are limited. Most of the evidence base consists of:

• In vitro CYP2C19 inhibition studies for each PPI, establishing Ki values
• Clinical pharmacokinetic studies of modafinil's CYP enzyme effects from the original FDA approval dataset [2]
• PPI pharmacokinetic studies stratified by CYP2C19 genotype, such as those published in Gastroenterology and Clinical Pharmacokinetics [3, 5]
• Population pharmacokinetic modeling that predicts interaction magnitude from the individual drug parameters

The absence of a dedicated modafinil-plus-PPI pharmacokinetic trial is a genuine gap. Interaction databases fill this gap through mechanistic extrapolation, which is reliable for CYP enzyme interactions but less precise about the exact AUC shifts in real-world patients on multiple other medications.